Skip to content
Investigational comparisonAugust 2, 2026 · 7 min read

Retatrutide vs. tirzepatide: an approved drug and an investigational one

In short: This is not a comparison between two available medications. Tirzepatide is approved and prescribable. Retatrutide is still in trials, cannot lawfully be compounded, and is not available by prescription.

Edited by

· Co-founder & CTO, Savo Group

B.S. in Computer Science, Oregon State University · B.A. in Psychology, University of Washington, Seattle

Clinical researchers reviewing investigational trial data for an unapproved weight medication

Current status

One is not approved

Retatrutide remains investigational. Any consumer product marketed as compounded or research-grade retatrutide is not an approved treatment.

Tirzepatide
FDA-approved
Retatrutide
Investigational
Available by prescription
Tirzepatide only
At a glance

Retatrutide vs. tirzepatide at product level

The first row is the one that matters. Everything below it is a comparison between something you can be prescribed and something you cannot.

Swipe horizontally to compare →

Retatrutide vs. tirzepatide at product level. The first row is the one that matters. Everything below it is a comparison between something you can be prescribed and something you cannot.
DetailTirzepatideRetatrutide
Regulatory statusFDA-approvedInvestigational, not approved
Available by prescriptionYesNo
Receptor actionGIP and GLP-1GIP, GLP-1 and glucagon
Sold asZepbound, MounjaroNothing lawfully sold to consumers
Can be compoundedCompounded preparations exist and are not approved productsNo. FDA says it cannot be used in compounding

Table source:FDA guidance on unapproved GLP-1 products

01

Only one of these is a medication you can be prescribed

Tirzepatide is approved by the FDA and is sold as Zepbound for weight management and Mounjaro for type 2 diabetes. A licensed clinician evaluates you and writes for it.

Retatrutide has reported trial results and is not approved. There is no lawful route to a retatrutide prescription in the United States today, and the FDA has stated it cannot be used in compounding. Anything offered for sale under that name is outside the approval system entirely.

02

What the third receptor is about

Tirzepatide acts on two receptors, GIP and GLP-1. Retatrutide is being studied as a triple agonist, adding glucagon receptor activity to those two.

That is a genuine difference in design and it is why the trial results have drawn attention. It is not a difference you can act on. Acting on it means buying an unapproved drug from an unregulated seller.

03

How to recognize an offer that should be refused

Sellers describe unapproved retatrutide as research-grade, research-use-only, or compounded. None of those descriptions make it a treatment. The last describes something the FDA has said cannot lawfully be done with this ingredient.

A legitimate weight-care clinic will not offer it. If a program does, that tells you what to conclude about the rest of what it offers.

  • Marketed as research-grade or research-use-only: not a medicine for human use.
  • Sold as compounded retatrutide: FDA says the ingredient cannot be used in compounding.
  • Sold without a clinician evaluation: outside the prescription system altogether.
Interest in retatrutide is reasonable. Buying something labelled with its name today is not the same thing, and the two are worth keeping separate.

Common questions

Answers to clarify the comparison

Is retatrutide better than tirzepatide?
Trial results have been reported and retatrutide is designed to act on a third receptor. It is investigational and not approved. Only one of these two can be prescribed, so a comparison of outcomes has nowhere to go.
Can I get retatrutide from a compounding pharmacy?
No. The FDA has stated that retatrutide cannot be used in compounding under federal law. Products marketed as compounded retatrutide are not approved treatments and are outside the system that reviews what is sold to patients.
When will retatrutide be available?
There is no approval date to report. It remains in trials, and a timeline offered by a seller rather than by the manufacturer or the FDA is marketing.

Primary sources

Read the official material behind this page

Health information is educational and does not diagnose, determine eligibility, or replace product labeling and care from a qualified professional.